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Summary.-The effect of methotrexate on solid rodent tumours has been in-
vestigated using the spontaneous mammary adenocarcinoma of the female C3H/Bts
mouse. As these tumours exhibit a wide range of volume doubling times, cal-
culations of tumour response to methotrexate must be related to doubling time.
When methotrexate is injected into the tumour a dose-dependent tumour response
is obtained. Systemic citrovorum " rescue " prevents methotrexate lethalities
but reduces tumour response by a factor of 2. Methotrexate-treated tumours have
an increased volume doubling time post treatment.
THE FOLIC ACID antagonist metho-
trexate (amethopterin, 4-amino-10-methyl
folic acid) has been used clinically in
attempts to control a variety of tumours
in man. There is, however, very little
recorded information as to its effect on
solid animal tumours, whether spon-
taneously occurring or transplanted, and
what there is is contradictory. As work
in this department was directed at
evaluating the efficacy of combining
chemotherapy and radiotherapy, using
the spontaneous C3H mammary adeno-
carcinoma as a model, it was necessary
to see whether despite conflicting reports
in the literature methotrexate would
produce detectable effects on this tumour
system.
MATERIALS AND METHODS
Animals.-Female mice bearing spon-
taneous mammary tumours were withdrawn
from the C3H/Bts stock colony and caged
8 to a box. They were fed Dixon's CDDM
diet with water ad libitum. Tumours had
been detected by palpation of the flanks of
the mice in the stock colony: the smallest
tumour detectable by this routine is about
the size of an enlarged inguinal lymph node,
2 mm3. As the supply of tumour-bearing
mice runs at about 8-15 per week, experi-
mental groups were made up by allocating
new batches of tumour mice randomly
between the different treatment groups to
ensure an even distribution of initial tumour
size.
Tu9mour measurement. All spontaneous
tumours are measured 3 times a week wNith
Vernier calipers, and the product of 3
diameters at right angles to each other is
used as an index of tumour volume. This
tumour volume" is plotted against time
on a semilog plot to calculate the tumour
doubling time. Over the initial stages
of tumour growN-th, until a volume of
3000-4000 mm3 is reached, the semilog
plot approximates closely to an exponential
relationship. Initial doubling times are cal-
culated over the exponential stage of tumour
growth, before the line starts to plateau.
The response of the tumour to metho-
trexate was calculated according to the
method described by Cheshire and Lindop
(1969) for assessing radiation response. The
volume of the tumour at the time of treat-
ment is calculated from the best fitting
pretreatment growAth line. After treatment,
when the tumour either fails to grow for an
interval, or shrinks and t-hen starts to re-EFFECT OF METHOTREXATE ON ADENOCARCINOMATA IN MICE
grow, the tumour response to any given dose
of the drug is calculated from the formula:
time for tumour to regain volume at treatment
post-treatment doubling time
A formula of this type is essential for the
analysis of the response of spontaneous
tumours since tumour doubling times are
variable and treatment may modify the
post-treatment doubling time. Calculations
based only on the delay of growth are
misleading since this will underestimate
effects on faster growing tumours and over-
estimate the response of the slower growing
tumours. Figure 1 is a histogram of tumour
doubling times measured in 124 mice con-
secutively developing mammary tumours.
The distribution is skewA, with a considerable
tail of very slowly growing tumours. All
tumour-bearinox mice in the colony are
examined post mortem and all tumours are
examined histologically. No correlation be-
twteen histological type of adenocarcinoma
and doubling time has been established.
Histological classification of spontaneous
maammu7ary tu,nourrs. A little under 50/c of
spontaneous mammary tumours in the
C3H/Bts colony are fibrosarcomata arising
from the supporting tissues of the mammary
gland. These can be detected clinically by
their firmness and adhesion to skin and
body uwall, and were not included in the
present study. All other mammary tumours
found in this survey have been considered
to be adenocarcinomata. Nearly all of
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these (92%/0) are extremely homogeneous,
simple acinar structures (_ Dunn's Type
A). As the tumours grow, they become
more cystic and blood lakes form (-Dunn's
Type C). This is not usually seen until
the relative volume is 6000-8000 mm3. A
small proportion of tumours have a papillary
(3%O) or macroglandular (5%o) formation.
Subsequent mammary tumour develop-
ment.-A high proportion of mice in the
C3H/Bts colony develop second and subse-
quent mammary tumours, exceptionally bear-
ing 7 discrete tumours along the milk crest.
With mice whose first primary tumour is
successfully treated, whether by drugs or
radiation, the incidence ofsubsequent tumour
formation increases, as life span may be
prolonged. In these experiments only the
first tumour to develop was treated with
methotrexate. Second and subsequent tu-
mours tend to have shorter volume doubling
times than the first tumouirs (Fig. 2).
RESULTS
Methotrexate toxicity
As methotrexate blocks folic acid
synthesis, the first cells to exhibit injury
after its administration are the rapidly
dividing cells of the intestinal epithelium.
The picture of methotrexate toxicity is
the same in all strains of mice although
the dose of methotrexate needed to
produce it varies considerably from strain
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Fi;. I. Distributioin of tumour volume (loubling times in 124 female C3H/Bts mice with sporn-
taneous mammary tumours.
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FIG. 2.-Comparison of tumour volume doubling times in 30 female C3H/Bts mice developing 2
spontaneous mammary tumours.
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FIG. 3. Methotrexate toxicity at 30 days after intraperitoneal injection in (a) tumour bearing
C3H/Bts female mice, (b) C3H/Bts female mice in which tumours had not yet developed and
(c) C3H/Bts male mice. Probit analysis lines fitted to mortality data, 8-10 mice per dose point.
to strain and with dose regimen. Beren-
baum and Brown (1965) reported an
LD50/7 of 30 mg/kg for male A2G mice,
and Griswold et al. (1963) an LD50 of
4'5 mg/kg/day for 7 days for Swiss mice.
C3H mice are more resistant, as male
C3H/Bts mice were found to have an
LD50/30 of 119-4 mg/kg 4-3 (Fig. 3c)
for methotrexate given intraperitoneally,
but female C3H/Bts (Fig. 3b) mice are
less tolerant, the LD50130 being 8541
mg/kg ± 4-3. The systemic tolerance of
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mice either intraperitoneally or into the
tumour, directing the needle centrally
into the tumour towards the body wall
and injecting very slowly. Deaths occur
6-9 days after intraperitoneal injections
and 7-12 days after intratumour injec-
tions, indicating slower systemic absorp-
tion from the tumour injection route.
From Fig. 5 it can be seen that intra-
peritoneal administration is an unsatis-
factory method for tumour treatment.
No dose response relationship is obtained,
probably because at the higher dose
levels the mortality is high. Intratumour
administration of methotrexate gave con-
sistently better results and increasing
the dose of methotrexate increased the
tumour response.
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FIG. 4. Weight loss in C3H/Bts male mice-
4 days after intraperitoneal injection of
methotrexate. Vertical bars represent
s.e. mean.
tumour-bearing C3H/Bts female mice
is reduced still further to an LD50/30 of
48-0 mg/kg + 5-6 (Fig. 3a).
Mice dying after an overdose of
methotrexate exhibit few external symp-
toms other thandiarrhoea accompanied by
weight loss, which is evident from 3 days
after intraperitoneal administration. The
degree of weight loss 4 days after adminis-
tration is dose dependent (Fig. 4). At
post-mortem examination, the livers of
mice dying from methotrexate poisoning
are bile-stained and fatty, with con-
spicuous fat globules inside the distended
hepatic cells.
Effect of methotrexate administration on
tumour growth
Methotrexate was injected as a saline
suspension (50 mg/ml) to tumour-bearing
Relationship between response to metho-
trexate and initial doubling time of tumour
Over a wide range of doubling times
the response of the tumour to metho-
trexate was independent oftumour growth
rate. At the extreme ranges of tumours
tested (Fig. 6) tumours which had very
fast volume doubling times exhibited a
much greater response to the same dose
of methotrexate than did more slowly
growing tumours of the same volume at
injection. Extremely slow-growing tu-
mours gave a poor response even with
the highest tolerated dose. It must be
stressed that this effect cannot be simply
explained by a greater degree of necrotic
tissue being present in either of these
extremes of growth rate. The simple
acinar structure of the typical mammary
tumour of this mouse colony is found
in tumours of up to 12,000 mm3 relative
volume without marked necrosis, and it
is quite impossible in this series to guess
what the doubling time of the tumour
would have been from examining its
histological appearance.
Effect of methotrexate treatment on tumour
doubling time
In general, the growth of the tumour
after methotrexate treatment was slower
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FIG. 5.-Tumour response to methotrexate. (a), methotrexate injected intraperitoneally. (b),
methotrexate injected into the tumour. Dotted lines show response when methotrexate ad-
ministration is followed by citrovorum rescue. Vertical bars represent ± s.e mean.
than that of the same tumour before
injection. In a series of 32 mouse tu-
mours with volume doubling times cal-
culated before and after treatment with
80 mg/kg methotrexate followed by citro-
vorum rescue the mean pretreatment
doubling time was 12-4 4i 2-4 days while
the mean post-treatment time was
22*0 ± 2*2 days, a significant difference
(0-005 < P < 0.001).
Hi8tological finding8
The pattern of histological damage to
be seen in the methotrexate-treated
tumours was examined in a small group
(24) of tumour-bearing mice which were
injected with 80 mg/kg into the tumour
and killed serially, 2 mice a day for 12
days. Damage to the intestinal crypt
epithelium was clearly demonstrated by
the absence of mitotic figures in the
crypt cells at 3 and 4 days, and by damage
to the villi. Some mitosis starts again
at 5 days and by 8 days surviving mice
show no intestinal damage. Weight loss
is halted 6 days after injection and initial
body weight regained 12 days afterwards.
These results follow the pattern described
for damage and methotrexate injury to
the mouse gut by Eder, Rostock and
Vogel (1967) but recovery starts one day
later here, probably due to the use of
intratumour injections.
One day after intratumour injection,
injected tumours show no damage apart
from localized disruption oftissues around
the injected area. After 4 days there are
areas of localized haemorrhage and dead
cells, and these are still present, although
decreasing in size, up to 8-11 days after
injection. Although the spleens of mice
injected with methotrexate are smaller
than those of normal mice, they contain
large amounts of haem breakdown prod-
ucts 4, 5 and 6 days after injection.
The metabolic block produced by
antifolates can be circumvented by ad-
ministering citrovorum factor (leucovorin
tetrahydrofolate) 24 h after the antifolate.
Goldin et al. (1954) showed this in leuk-
aemic DBA male mice after aminopterin
injection, and Berenbaum (1964) demon-
strated citrovorum rescue in guinea-pigs
214
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citrovorum rescue it can be seen that no
matter which route of administration is
used for the methotrexate the response
of the tumour is decreased. Figure 5
shows that when citrovorum " rescue " is
carried out 24 h after intraperitoneal
methotrexate the tumour response is
reduced by a factor of 2-8 at the 40 mg/kg
dose level, and 2-2 at the 60 mg/kg level.
Less reduction of tumour response was
seen when intratumour injection ofmetho-
trexate was followed by citrovorum rescue
as the tumour response to methotrexate
was reduced by a factor of 2-1 at 60 mg/kg
and 1P9 at 80 mg/kg (Fig. 5). The
optimum dose for intratumour injection
was 80 mg/kg followed by citrovorum
rescue.
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FIG. 6.-Relationship between initial tumour
volume doubling time and response to
80 mg/kg methotrexate intratumour fol-
lowed by citrovorum rescue. Note break
in scale on ordinate. Data from 32
mice.
given methotrexate. Bypass ofthe meta-
bolic block produced by methotrexate in
all dividing tissues is used clinically to
control the systemic toxicity of metho-
trexate. In the tumour bearing mice
used here " rescue " was only obtained
with 200 mg/kg leucovorin given sub-
cutaneously 24 h after methotrexate ad-
ministration. Incomplete reversal of the
methotrexate-induced block of folic acid
synthesis with 100 mg/kg leucovorin will
protect the mouse only against the LD60
rather than the LD90 dose of metho-
trexate.
When the tumour response to metho-
trexate is compared with the effect of the
same dose of methotrexate followed by
DISCUSSION
Transplanted rodent tumour systems
have been widely used in screening tests
for cancer chemotherapeutic agents.
Spontaneously arising tumour systems,
with their slower rates of growth, better
vascularization and less necrosis, are
arguably a better model for experimental
therapeutic regimens than are trans-
planted tumours, quite apart from im-
munological considerations. Methotrex-
ate, a phase-specific antifolate, has been
widely used in clinical practice for 15
years or more. It is therefore surprising
to find in the literature a general belief
that methotrexate is without effect on
solid rodent tumours, either transplanted
tumours (Skipper and Schmidt, 1962)
or spontaneous mouse adenocarcinoma
(Hirschberg, 1963). Spontaneous rodent
tumours may be more refractory to
chemotherapy than are transplanted ro-
dent tumours. One approach to over-
coming this difficulty has been based on
the expectation that very small amounts
of spontaneous tumour tissue would be
more responsive to chemotherapy than
larger volumes, and effective experimental
combinations of surgical removal of tu-
mours and drug administration have been
described by Humphreys, Mantel and
70-.
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Goldin (1966) and Stolfi, Martin and
Fugmann (1971).
Early experiments by Scholler, Phillips
and Bittner (1955) using not a true
spontaneous tumour but a first generation
transplant, produced equivocal effects on
inhibition of tumour growth with no
increased survival with daily doses of
4-8 mg/kg. The technique used for meth-
otrexate administration in the experi-
ments described here consisted ofinjecting
one large single dose of methotrexate into
the tumour, followed 24 h afterwards by
citrovorum rescue. There is a consider-
ableamount ofboth clinical(Sullivan, 1962)
and experimental (Delmonte and Jukes,
1962) evidence that shows that fraction-
ated administration of methotrexate re-
sults in greater toxicity than does ad-
ministration of the same dose singly.
The increased toxicity of daily doses in
the experiment reported by Scholler et
al. (1955) may have masked any chemo-
therapeutic effect on the tumour. The
wide range of doubling times of the
spontaneous mouse mammary adenocar-
cinoma makes it essential that all cal-
culations of the response of this tumour
to drugs based on changes in volume
should utilize the inherent doubling time
of the tumour in the calculation. Mean
times for tumour recession, or growth
retardation, are too insensitive to be
satisfactory endpoints. The route of ad-
ministration is also important. In the
experiments described here better results
were obtained when methotrexate was
injected directly into the tumour, and
the subsequent rescuing citrovorum in-
jection was made subcutaneously, than
when methotrexate was given intraperi-
toneally. Using these methods, a small
but significant response to methotrexate
may readily be demonstrated.
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